Innoviva, Inc. (INVA)Stock Price & Financial Statements
AboutInnoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Show more
- Revenue $425M +18.5%
- EBITDA $204M +5.8%
- Net Income $271M +1059.2%
- EPS (Diluted) 3.30 +816.7%
- Gross Margin 72.33% -19.4%
- EBITDA Margin 47.98% -10.7%
- Operating Margin 38.52% -17.2%
- Net Margin 63.78% +878.1%
- ROE 29.09% +749.6%
- ROIC 16.83% +18.9%
- Debt/Equity -
- Interest Coverage 9.81 +30.5%
Key Insights
Based on financial data analysisStrengths
- ✓Excellent 3Y average ROE of 20.5%
- ✓FCF machine: 46.1% free cash flow margin
- ✓Healthy 5Y average net margin of 52.1%
Weaknesses
- ✗Shares diluted 14.3% in last year
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y22.93%
5Y4.77%
3Y8.66%
TTM14.52%
Profit (Net Income) CAGR
10Y-
5Y3.86%
3Y8.22%
TTM1059.22%
EPS CAGR
10Y-
5Y10.31%
3Y11.67%
TTM1701.54%
ROCE
10Y Avg28.06%
5Y Avg14.5%
3Y Avg12.32%
Latest12.36%
Peer Comparison
Royalty and IP Monetization Vehicles| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 BTXBlackRock Technology and Private Equity Term Trust | 772.62M | 6.62 | 38.94 | -81.13% | 87.75% | 1.87% | 35.88% | |
 RPRXRoyalty Pharma plc | 26.77B | 47.43 | 26.65 | 5.06% | 32.55% | 7.95% | 9.3% | 0.91 |
INVAInnoviva, Inc. | 1.7B | 22.73 | 6.89 | 18.52% | 65.38% | 23.12% | 11.54% | |
 CDTCDT Equity Inc. | 1.46M | 0.71 | -0.03 | -474.64% | ||||
 CBUSCibus, Inc. | 98.77M | 3.33 | -0.31 | 134.56% | -31.34% | -228.53% | 0.37 | |
 XOMAPXOMA Corporation | 317.24M | 25.77 | -15.62 | 498.72% | 46.15% | 20.14% | 1.46 | |
 XOMAXOMA Royalty Corp. | 316.14M | 26.45 | -16.03 | 498.72% | 41.06% | 17.91% | 1.46 | |
 LGNDLigand Pharmaceuticals Incorporated | 4.11B | 208.95 | -949.77 | 27.28% | 19.34% | 5.11% | 1.88% | 0.01 |
Compare INVA vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 133.57M | 217.22M | 261M | 261.02M | 336.79M | 391.87M | 331.34M | 310.46M | 358.71M | 425.13M |
| Revenue Growth % | 147.58% | 62.63% | 20.16% | 0% | 29.03% | 16.35% | -15.45% | -6.3% | 15.54% | 18.52% |
| Cost of Goods Sold | 1.39M | 1.35M | 0 | 0 | 0 | 0 | 13.79M | 42.64M | 36.6M | 117.61M |
| COGS % of Revenue | 1.04% | 0.62% | - | - | - | - | 4.16% | 13.73% | 10.2% | 27.67% |
| Gross Profit | 132.18M | 215.86M | 261M | 261.02M | 336.79M | 391.87M | 317.55M | 267.82M | 322.11M | 307.52M |
| Gross Margin % | 98.96% | 99.38% | 100% | 100% | 100% | 100% | 95.84% | 86.27% | 89.8% | 72.33% |
| Gross Profit Growth % | 157.5% | 63.31% | 20.91% | 0% | 29.03% | 16.35% | -18.97% | -15.66% | 20.27% | -4.53% |
| Operating Expenses | 24.58M | 25.5M | 17.05M | 14.66M | 15.67M | 16.76M | 354.49M | 153.94M | 155.25M | 143.77M |
| OpEx % of Revenue | 18.4% | 11.74% | 6.53% | 5.62% | 4.65% | 4.28% | 106.99% | 49.58% | 43.28% | 33.82% |
| Selling, General & Admin | 23.19M | 24.15M | 17.05M | 14.66M | 13.88M | 16.19M | 63.54M | 98.23M | 115.69M | 113.17M |
| SG&A % of Revenue | 17.36% | 11.12% | 6.53% | 5.62% | 4.12% | 4.13% | 19.18% | 31.64% | 32.25% | 26.62% |
| Research & Development | 1.39M | 1.35M | 0 | 0 | 1.79M | 576K | 41.43M | 33.92M | 13.65M | 30.6M |
| R&D % of Revenue | 1.04% | 0.62% | - | - | 0.53% | 0.15% | 12.5% | 10.93% | 3.81% | 7.2% |
| Other Operating Expenses | 2.38M | -7.04M | 0 | 0 | 0 | 0 | 249.52M | 21.78M | 25.9M | 0 |
| Operating Income | 108.99M | 183.6M | 238.25M | 246.36M | 321.12M | 375.1M | -36.95M | 113.89M | 166.87M | 163.75M |
| Operating Margin % | 81.6% | 84.53% | 91.28% | 94.38% | 95.35% | 95.72% | -11.15% | 36.68% | 46.52% | 38.52% |
| Operating Income Growth % | 245.12% | 68.46% | 29.76% | 3.4% | 30.35% | 16.81% | -109.85% | 408.25% | 46.52% | -1.87% |
| EBITDA | 122.94M | 197.59M | 252.12M | 260.23M | 372.58M | 464.35M | -31.36M | 135.67M | 192.77M | 203.97M |
| EBITDA Margin % | 92.04% | 90.96% | 96.6% | 99.7% | 110.62% | 118.5% | -9.47% | 43.7% | 53.74% | 47.98% |
| EBITDA Growth % | 170.13% | 60.71% | 27.6% | 3.22% | 43.17% | 24.63% | -106.75% | 532.55% | 42.09% | 5.81% |
| D&A (Non-Cash Add-back) | 13.95M | 13.98M | 13.87M | 13.87M | 0 | 0 | 5.58M | 21.78M | 25.9M | 40.23M |
| EBIT | 108.99M | 183.6M | 234.21M | 246.36M | 372.58M | 464.35M | 302.74M | 213.25M | 59.6M | 163.75M |
| Net Interest Income | -51.83M | -42.29M | -22.29M | -13.12M | -16.81M | -17.23M | -9.42M | -3.34M | -3.07M | 4.39M |
| Interest Income | 582K | 1.31M | 1.66M | 5.54M | 1.52M | 1.84M | 6.37M | 15.82M | 19.14M | 21.09M |
| Interest Expense | 52.42M | 43.6M | 23.95M | 18.66M | 18.33M | 19.07M | 15.79M | 19.16M | 22.21M | 16.7M |
| Other Income/Expense | -49.45M | -49.33M | -28M | -13.46M | 33.12M | 70.17M | 323.89M | 80.21M | -129.48M | 163.12M |
| Pretax Income | 59.54M | 134.27M | 210.25M | 232.9M | 354.25M | 445.28M | 286.95M | 194.1M | 37.39M | 326.86M |
| Pretax Margin % | 44.57% | 61.81% | 80.56% | 89.23% | 105.18% | 113.63% | 86.6% | 62.52% | 10.42% | 76.89% |
| Income Tax | 0 | 0 | -196.07M | 41.9M | 60.43M | 76.44M | 66.69M | 14.38M | 14M | 55.7M |
| Effective Tax Rate % | 100% | 99.9% | 187.89% | 67.54% | 63.35% | 59.71% | 74.55% | 92.59% | 62.57% | 82.96% |
| Net Income | 59.54M | 134.14M | 395.06M | 157.29M | 224.4M | 265.85M | 213.92M | 179.72M | 23.39M | 271.17M |
| Net Margin % | 44.57% | 61.76% | 151.36% | 60.26% | 66.63% | 67.84% | 64.56% | 57.89% | 6.52% | 63.78% |
| Net Income Growth % | 417.36% | 125.31% | 194.5% | -60.19% | 42.67% | 18.47% | -19.53% | -15.99% | -86.98% | 1059.22% |
| Net Income (Continuing) | 59.54M | 134.27M | 406.33M | 190.99M | 293.81M | 368.84M | 220.26M | 179.72M | 23.39M | 271.17M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 152K | 5.47M | 28.62M | 67.92M | 111.19M | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.53 | 1.17 | 3.48 | 1.43 | 2.02 | 2.87 | 2.37 | 2.20 | 0.36 | 3.30 |
| EPS Growth % | 431.25% | 120.75% | 197.44% | -58.91% | 41.26% | 42.08% | -17.42% | -7.17% | -83.64% | 816.67% |
| EPS (Basic) | 0.54 | 1.25 | 3.53 | 1.56 | 2.21 | 3.24 | 3.07 | 2.92 | 0.37 | 4.02 |
| Diluted Shares Outstanding | 123.23M | 119.87M | 113.41M | 113.41M | 113.55M | 94.31M | 95.25M | 86.88M | 74.19M | 84.76M |
| Basic Shares Outstanding | 110.28M | 106.94M | 100.85M | 101.15M | 101.32M | 82.06M | 69.64M | 65.44M | 62.73M | 67.39M |
| Dividend Payout Ratio | 1.61% | 0.21% | 0.02% | 0.01% | - | - | - | - | - | - |
Balance Sheet
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 198.05M | 199.62M | 199.04M | 431.23M | 342.06M | 313.67M | 443.51M | 344.22M | 554.31M | 727.51M |
| Cash & Short-Term Investments | 150.43M | 129.07M | 114.91M | 350.85M | 246.49M | 201.53M | 291.05M | 193.51M | 412.5M | 550.94M |
| Cash Only | 118.02M | 73.34M | 62.42M | 278.1M | 246.49M | 201.53M | 291.05M | 193.51M | 304.96M | 550.94M |
| Short-Term Investments | 32.42M | 55.74M | 52.49M | 72.75M | 0 | 0 | 0 | 0 | 107.53M | 0 |
| Accounts Receivable | 46.85M | 70.54M | 83.29M | 79.43M | 93.93M | 110.71M | 64.07M | 84.08M | 86.37M | 34.97M |
| Days Sales Outstanding | 128.02 | 118.53 | 116.47 | 111.07 | 101.8 | 103.12 | 70.58 | 98.84 | 87.88 | 30.02 |
| Inventory | -46.85M | -754K | -83.29M | 0 | 0 | 0 | 55.9M | 40.74M | 33.73M | 39.17M |
| Days Inventory Outstanding | - | - | - | - | - | - | 1.48K | 348.71 | 336.35 | 121.57 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 70K | 2.93M | 4.26M | 656K | 102.44M |
| Total Non-Current Assets | 180.95M | 167.72M | 349.15M | 293.59M | 657.51M | 612.72M | 787.99M | 899.29M | 746.75M | 907.65M |
| Property, Plant & Equipment | 368K | 209K | 160K | 33K | 28K | 109K | 3.44M | 3.02M | 2.97M | 12.48M |
| Fixed Asset Turnover | 362.96x | 1039.32x | 1631.28x | 7909.58x | 12028.36x | 3595.10x | 96.46x | 102.84x | 120.90x | 34.05x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 26.71M | 17.91M | 17.91M | 17.91M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 252.92M | 230.34M | 208.43M | 182.16M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 438.26M | 483.85M | 403.01M | 560.98M | 393.96M | 193.73M |
| Other Non-Current Assets | 180.58M | 167.51M | 152.94M | 139.39M | 125.47M | 128.77M | 101.91M | 87.05M | 111.44M | 501.38M |
| Total Assets | 379M | 367.34M | 548.19M | 724.83M | 999.57M | 926.39M | 1.23B | 1.24B | 1.3B | 1.64B |
| Asset Turnover | 0.35x | 0.59x | 0.48x | 0.36x | 0.34x | 0.42x | 0.27x | 0.25x | 0.28x | 0.26x |
| Asset Growth % | -10.63% | -3.08% | 49.23% | 32.22% | 37.9% | -7.32% | 32.93% | 0.98% | 4.63% | 25.68% |
| Total Current Liabilities | 11.41M | 9.74M | 5.7M | 5.37M | 6.11M | 5.81M | 134.97M | 38.13M | 236.08M | 49.7M |
| Accounts Payable | 128K | 601K | 11K | 10K | 66K | 27K | 2.94M | 6.72M | 2.13M | 4.97M |
| Days Payables Outstanding | 33.54 | 161.89 | - | - | - | - | 77.77 | 57.5 | 21.26 | 15.41 |
| Short-Term Debt | 7.75M | 25M | 0 | 0 | 0 | 0 | 96.19M | 0 | 192.03M | 0 |
| Deferred Revenue (Current) | 885K | -19.68M | 0 | 0 | 0 | 0 | 2.09M | 1.28M | 1.13M | 4.27M |
| Other Current Liabilities | 0 | 0 | 5.22M | 4.71M | 0 | 0 | 2.64M | 0 | 6.44M | 40.46M |
| Current Ratio | 17.35x | 20.49x | 34.92x | 80.29x | 55.98x | 54.02x | 3.29x | 9.03x | 2.35x | 14.64x |
| Quick Ratio | 21.46x | 20.57x | 49.53x | 80.29x | 55.98x | 54.02x | 2.87x | 7.96x | 2.21x | 13.85x |
| Cash Conversion Cycle | - | - | - | - | - | - | 1.47K | 390.06 | 402.96 | 136.18 |
| Total Non-Current Liabilities | 720.58M | 600.3M | 383.44M | 377.34M | 385.62M | 394.65M | 530.74M | 530.42M | 373.82M | 412.63M |
| Long-Term Debt | 708.34M | 574.36M | 382.86M | 377.12M | 385.52M | 394.65M | 444.18M | 446.23M | 256.32M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 2.38M | 1.64M | 1.18M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 5.77M | 563K | 0 | 31.79M |
| Other Non-Current Liabilities | 1.38M | 940K | 586K | 219K | 106K | 1 | 78.41M | 81.99M | 116.32M | 380.83M |
| Total Liabilities | 731.99M | 610.04M | 389.14M | 382.71M | 391.73M | 400.46M | 665.71M | 568.55M | 609.9M | 462.32M |
| Total Debt | 716.09M | 599.36M | 382.86M | 377.12M | 385.52M | 394.76M | 544.07M | 449.08M | 451.1M | 0 |
| Net Debt | 598.08M | 526.03M | 320.44M | 99.02M | 139.03M | 193.23M | 253.02M | 255.56M | 146.13M | -550.94M |
| Debt / Equity | - | - | 2.41x | 1.10x | 0.63x | 0.75x | 0.96x | 0.67x | 0.65x | - |
| Debt / EBITDA | 5.82x | 3.03x | 1.52x | 1.45x | 1.03x | 0.85x | - | 3.31x | 2.34x | - |
| Net Debt / EBITDA | 4.86x | 2.66x | 1.27x | 0.38x | 0.37x | 0.42x | - | 1.88x | 0.76x | -2.70x |
| Interest Coverage | 2.08x | 4.21x | 9.95x | 13.20x | 17.52x | 19.67x | -2.34x | 5.94x | 7.51x | 9.81x |
| Total Equity | -352.99M | -242.71M | 159.05M | 342.12M | 607.84M | 525.93M | 565.79M | 674.96M | 691.16M | 1.17B |
| Equity Growth % | -3.02% | 31.24% | 165.53% | 115.1% | 77.67% | -13.47% | 7.58% | 19.29% | 2.4% | 69.69% |
| Book Value per Share | -2.86 | -2.02 | 1.40 | 3.02 | 5.35 | 5.58 | 5.94 | 7.77 | 9.32 | 13.84 |
| Total Shareholders' Equity | -352.99M | -242.86M | 153.58M | 313.5M | 539.91M | 414.74M | 565.79M | 674.96M | 691.16M | 1.17B |
| Common Stock | 1.08M | 1.02M | 1.01M | 1.01M | 1.01M | 696K | 692K | 633K | 627K | 747K |
| Retained Earnings | -1.63B | -1.5B | -1.1B | -946.4M | -722M | -456.15M | -204.91M | -25.19M | -1.8M | 269.37M |
| Treasury Stock | -3.26M | -3.26M | 0 | 0 | 0 | -393.83M | -393.83M | -393.83M | 0 | 0 |
| Accumulated OCI | 1K | -18K | -3K | 27K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 152K | 5.47M | 28.62M | 67.92M | 111.19M | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 60.98M | 141.75M | 223.53M | 257.46M | 313.11M | 363.81M | 201.73M | 141.06M | 188.69M | 196.93M |
| Operating CF Margin % | 45.66% | 65.26% | 85.64% | 98.64% | 92.97% | 92.84% | 60.88% | 45.44% | 52.6% | 46.32% |
| Operating CF Growth % | 501.95% | 132.43% | 57.7% | 15.18% | 21.62% | 16.19% | -44.55% | -30.07% | 33.76% | 4.37% |
| Net Income | 59.54M | 134.27M | 406.33M | 190.99M | 293.81M | 368.84M | 220.26M | 179.72M | 23.39M | 271.17M |
| Depreciation & Amortization | 13.95M | 13.98M | 13.87M | 13.87M | 0 | 13.83M | 19.51M | 35.7M | 39.85M | 40.23M |
| Stock-Based Compensation | 8.3M | 9.83M | 3.23M | 2.06M | 1.7M | 2.02M | 7.35M | 5.84M | 6.37M | 9.45M |
| Deferred Taxes | -2.35M | 7.15M | -196.05M | 41.88M | 60.42M | 76.43M | 25.01M | 4.4M | -12.62M | 43.85M |
| Other Non-Cash Items | 1.16M | 11.94M | 12.91M | 5.57M | -28.5M | -80.43M | -77.27M | -59.81M | 138.62M | -167.76M |
| Working Capital Changes | -21.96M | -28.28M | -16.76M | 3.1M | -14.32M | -16.87M | 6.87M | -24.79M | -6.93M | 0 |
| Change in Receivables | -20.62M | -23.69M | -12.75M | 3.86M | -14.5M | -16.78M | 9.79M | -20M | -2.29M | -14.57M |
| Change in Inventory | 230K | -1.96M | -3.43M | -664K | 0 | 0 | 280K | -12M | -6.81M | 4.84M |
| Change in Payables | -690K | 473K | -590K | -1K | 56K | -39K | 92K | 3.78M | -4.58M | 2.83M |
| Cash from Investing | -4.58M | -23.24M | 3.52M | -18M | -314.94M | 43.72M | -56.63M | -66.76M | -63.79M | 40.5M |
| Capital Expenditures | -278K | 0 | 0 | -12K | -13K | -1.3M | -67K | -411K | -270K | -1.13M |
| CapEx % of Revenue | 0.21% | - | - | 0% | 0% | 0.33% | 0.02% | 0.13% | 0.08% | 0.27% |
| Acquisitions | 0 | 0 | 0 | 17.99M | -102.86M | -235.81M | -33.2M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -4.3M | -23.24M | 3.52M | -17.99M | 0 | -20.98M | -56.63M | 0 | -3.9M | -929K |
| Cash from Financing | -97.57M | -163.19M | -237.97M | -23.78M | -29.79M | -452.5M | -55.57M | -171.84M | -13.45M | 8.55M |
| Debt Issued (Net) | -18.4M | -63.74M | -230M | -13.75M | 0 | 0 | 66.37M | -96.2M | 0 | 0 |
| Equity Issued (Net) | -1000K | -1000K | -1000K | 538K | 344K | -1000K | -1000K | -1000K | -1000K | 0 |
| Dividends Paid | -960K | -281K | -80K | -11K | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -79.17M | -99.63M | -3.07M | -89K | -92K | -394.21M | -8.59M | -75.81M | -14.92M | -4.53M |
| Other Financing | 0 | 458K | -5.96M | -10.55M | -30.13M | -59.46M | -113.35M | 0 | 0 | 8.55M |
| Net Change in Cash | -41.16M | -44.68M | -10.92M | 215.68M | -31.61M | -44.96M | 89.52M | -97.54M | 111.45M | 245.98M |
| Free Cash Flow | 60.71M | 141.75M | 223.53M | 257.45M | 313.1M | 362.51M | 201.66M | 140.65M | 188.42M | 195.8M |
| FCF Margin % | 45.45% | 65.26% | 85.64% | 98.63% | 92.96% | 92.51% | 60.86% | 45.3% | 52.53% | 46.06% |
| FCF Growth % | 499.62% | 133.5% | 57.7% | 15.17% | 21.62% | 15.78% | -44.37% | -30.25% | 33.96% | 3.92% |
| FCF per Share | 0.49 | 1.18 | 1.97 | 2.27 | 2.76 | 3.84 | 2.12 | 1.62 | 2.54 | 2.31 |
| FCF Conversion (FCF/Net Income) | 1.02x | 1.06x | 0.57x | 1.64x | 1.40x | 1.37x | 0.94x | 0.78x | 8.07x | 0.73x |
| Interest Paid | 0 | 0 | 0 | 0 | 9.93M | 0 | 11.74M | 0 | 10.36M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 53.85M | 0 | 11.79M | 0 |
Key Ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | 248.38% | 62.77% | 47.24% | 46.9% | 39.19% | 28.97% | 3.42% | 29.09% |
| Return on Invested Capital (ROIC) | 33.26% | 52.12% | 46.85% | 40.14% | 40.55% | 38.38% | -3.6% | 9.77% | 14.16% | 16.83% |
| Gross Margin | 98.96% | 99.38% | 100% | 100% | 100% | 100% | 95.84% | 86.27% | 89.8% | 72.33% |
| Net Margin | 44.57% | 61.76% | 151.36% | 60.26% | 66.63% | 67.84% | 64.56% | 57.89% | 6.52% | 63.78% |
| Debt / Equity | - | - | 2.41x | 1.10x | 0.63x | 0.75x | 0.96x | 0.67x | 0.65x | - |
| Interest Coverage | 2.08x | 4.21x | 9.95x | 13.20x | 17.52x | 19.67x | -2.34x | 5.94x | 7.51x | 9.81x |
| FCF Conversion | 1.02x | 1.06x | 0.57x | 1.64x | 1.40x | 1.37x | 0.94x | 0.78x | 8.07x | 0.73x |
| Revenue Growth | 147.58% | 62.63% | 20.16% | 0% | 29.03% | 16.35% | -15.45% | -6.3% | 15.54% | 18.52% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics